Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone646-661-7661
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees55
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions
What is Ovid Therapeutics' stock symbol?
Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."
How were Ovid Therapeutics' earnings last quarter?
Ovid Therapeutics Inc (NASDAQ:OVID) announced its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.08. View Ovid Therapeutics' Earnings History.
When is Ovid Therapeutics' next earnings date?
What price target have analysts set for OVID?
5 brokers have issued twelve-month target prices for Ovid Therapeutics' stock. Their forecasts range from $10.00 to $27.00. On average, they expect Ovid Therapeutics' stock price to reach $15.50 in the next year. This suggests a possible upside of 711.5% from the stock's current price. View Analyst Price Targets for Ovid Therapeutics.
What is the consensus analysts' recommendation for Ovid Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ovid Therapeutics.
What are Wall Street analysts saying about Ovid Therapeutics stock?
Here are some recent quotes from research analysts about Ovid Therapeutics stock:
- 1. According to Zacks Investment Research, "Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company's product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid Therapeutics Inc. is based in New York, United States. " (8/22/2019)
- 2. LADENBURG THALM/SH SH analysts commented, "We believe the new terms are much more favorable to Ovid (especially near-term) and demonstrate Lundbeck’s confidence in the potential of this Phase 3 ready candidate. The Amendment drops the near-term payment to Lundbeck for the start of the to $1M. As an offset, the total milestone payments are now $189M, from $181M. Given the pullback in OVID’s shares over the last year we find this important news for the company as well as its current and potential shareholders. We speculate that since Ovid’s CEO, Dr. Jeremy Levin, sits on Lundbeck’s Board, Lundbeck has greater confidence in the execution of the Phase 3 and its regulatory and commercial appeal than most outside partners would typically have in a company. Regardless, this Amendment frees up $9M for to deploy into the ongoing clinical development of OV101 and OV935." (5/16/2019)
Has Ovid Therapeutics been receiving favorable news coverage?
Media stories about OVID stock have trended positive on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ovid Therapeutics earned a news impact score of 2.5 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next several days. View News Stories for Ovid Therapeutics.
Are investors shorting Ovid Therapeutics?
Ovid Therapeutics saw a drop in short interest in the month of July. As of July 31st, there was short interest totalling 384,800 shares, a drop of 21.3% from the June 30th total of 488,900 shares. Based on an average trading volume of 324,400 shares, the short-interest ratio is currently 1.2 days. Currently, 1.7% of the company's shares are sold short. View Ovid Therapeutics' Current Options Chain.
Who are some of Ovid Therapeutics' key competitors?
Some companies that are related to Ovid Therapeutics include Clovis Oncology (CLVS), Xeris Pharmaceuticals (XERS), Mirum Pharmaceuticals (MIRM), ProQR Therapeutics (PRQR), Rigel Pharmaceuticals (RIGL), Assembly Biosciences (ASMB), BIOFRONTERA AG/ADR (BFRA), Theratechnologies (THERF), Protagonist Therapeutics (PTGX), OvaScience (OVAS), Kindred Biosciences (KIN), Prothena (PRTA), Arcus Biosciences (RCUS), Dynavax Technologies (DVAX) and Kalvista Pharmaceuticals (KALV).
What other stocks do shareholders of Ovid Therapeutics own?
Who are Ovid Therapeutics' key executives?
Ovid Therapeutics' management team includes the folowing people:
- Dr. Jeremy Max Levin, Chairman & CEO (Age 66)
- Dr. Matthew J. During, Founder, Chairman of Scientific Advisory Board & Director (Age 62)
- Ms. Lora Pike, Sr. Director of Investor Relations & PR
- Ms. Ana C. Ward Esq., M.S., M.B.A., Sr. VP, Gen. Counsel & Sec. (Age 50)
- Mr. Thomas Michael Perone, Sr. VP, Gen. Counsel & Sec.
When did Ovid Therapeutics IPO?
(OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.
Who are Ovid Therapeutics' major shareholders?
Ovid Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.84%), Cowen Inc. (2.51%), Cowen Inc. (2.51%), Renaissance Technologies LLC (1.22%), Wells Fargo & Company MN (1.14%) and Acadian Asset Management LLC (0.55%). Company insiders that own Ovid Therapeutics stock include Douglas E Williams, Jeremy M Levin and Karen Bernstein. View Institutional Ownership Trends for Ovid Therapeutics.
Which institutional investors are selling Ovid Therapeutics stock?
OVID stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Cowen Inc., Cowen Inc., Morgan Stanley, Charles Schwab Investment Management Inc., JPMorgan Chase & Co. and Northern Trust Corp. View Insider Buying and Selling for Ovid Therapeutics.
Which institutional investors are buying Ovid Therapeutics stock?
OVID stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Wells Fargo & Company MN, Renaissance Technologies LLC, Paloma Partners Management Co, Acadian Asset Management LLC and Jane Street Group LLC. Company insiders that have bought Ovid Therapeutics stock in the last two years include Douglas E Williams, Jeremy M Levin and Karen Bernstein. View Insider Buying and Selling for Ovid Therapeutics.
How do I buy shares of Ovid Therapeutics?
Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ovid Therapeutics' stock price today?
One share of OVID stock can currently be purchased for approximately $1.91.
How big of a company is Ovid Therapeutics?
Ovid Therapeutics has a market capitalization of $73.90 million. The company earns $-51,980,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Ovid Therapeutics employs 55 workers across the globe.View Additional Information About Ovid Therapeutics.
What is Ovid Therapeutics' official website?
How can I contact Ovid Therapeutics?
Ovid Therapeutics' mailing address is 1460 BROADWAY SUITE 15044, NEW YORK NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]
MarketBeat Community Rating for Ovid Therapeutics (NASDAQ OVID)
MarketBeat's community ratings are surveys of what our community members think about Ovid Therapeutics and other stocks. Vote "Outperform" if you believe OVID will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OVID will underperform the S&P 500 over the long term. You may vote once every thirty days.
